Phaseline

Targets › OSPAB

OSPAB: drug programs, companies and trials

1 program from 1 company in 9 trials: 5 Phase 3, 4 Phase 1; Infectious disease, Metabolic and endocrine, Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on OSPAB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerCMP 001
6-valent OspA-based Lyme disease vaccine
ESR1, OSPABPhase 3Lyme Disease; Advanced Malignancies; Lyme Borreliosis; Advanced Breast Cancer …Dec 2026

Conditions

Breast Cancer (2) Lyme Disease (1) Advanced Malignancies (1) Lyme Borreliosis (1) Advanced Breast Cancer (1) Pneumococcal Diseases (1) Obesity and Obesity-related Medical Conditions (1) Pneumococcal Disease (1)

Modalities

mixed (1)

Companies

Pfizer (1)

Related targets

ESR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.